Vaxneuvance 
Procedural steps taken and scientific information after the authorisation 
Application 
Scope 
number 
Opinion/ 
Commission 
Product 
Summary 
Notification1 
Decision 
Information 
issued on 
Issued2 / 
affected3  
amended 
on 
IB/0018 
B.II.f.1.b.5 - Stability of FP - Extension of the shelf 
16/11/2023 
SmPC 
life of the finished product - Biological/immunological 
medicinal product in accordance with an approved 
stability protocol 
1 Notifications are issued for type I variations and Article 61(3) notifications (unless part of a group including a type II variation or extension application or a worksharing application). Opinions 
are issued for all other procedures. 
2 A Commission decision (CD) is issued for procedures that affect the terms of the marketing authorisation (e.g. summary of product characteristics, annex II, labelling, package leaflet). The 
CD is issued within two months of the opinion for variations falling under the scope of Article 23.1a(a) of Regulation (EU) No. 712/2012, or within one year for other procedures. 
3 SmPC (Summary of Product Characteristics), Annex II, Labelling, PL (Package Leaflet). 
Official address  Domenico Scarlattilaan 6  ●  1083 HS Amsterdam  ●  The Netherlands 
Address for visits and deliveries  Refer to www.ema.europa.eu/how-to-find-us  
Send us a question  Go to www.ema.europa.eu/contact   Telephone +31 (0)88 781 6000 
An agency of the European Union 
 
 
 
 
 
 
  
 
 
 
 
 
PSUSA/10975
Periodic Safety Update EU Single assessment - 
31/08/2023 
n/a 
PRAC Recommendation - maintenance 
/202301 
pneumococcal polysaccharide conjugate vaccine (15 
valent, adsorbed) 
IB/0016 
B.I.d.1.a.4 - Stability of AS - Change in the re-test 
14/08/2023 
n/a 
period/storage period - Extension or introduction of a 
re-test period/storage period supported by real time 
data 
IB/0014 
B.IV.1.z - Change of a measuring or administration 
28/04/2023 
n/a 
device - Other variation 
II/0013/G 
This was an application for a group of variations. 
30/03/2023 
26/04/2023 
SmPC and PL 
For more information, please refer to the Summary of 
Product Characteristics. 
Grouped application comprising two type II 
variations as follows: 
- To update sections 4.2, 4.4, 4.8, 5.1 of the SmPC 
in order to add safety data on recipients of 
haematopoietic stem cell transplant (HSCT) based on 
final results from study V114-022, listed as a 
category 3 study in the RMP; This is a Clinical Study 
to Evaluate the Safety, Tolerability, and 
Immunogenicity of Vaxneuvance in Recipients of 
Allogeneic Hematopoietic Stem Cell Transplant. 
- To update sections 4.2, 5.1 of the SmPC in order to 
update the information regarding a 3-dose regimen 
based on final results from study V114-026; a 
Clinical Study to Evaluate the Safety, Tolerability, 
and Immunogenicity of a 3-dose Regimen of 
Vaxneuvance in Healthy Infants. 
The Package Leaflet is updated accordingly. 
Page 2/6 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
The RMP version 3.0 (consolidated) has been 
submitted. 
C.I.4 - Change(s) in the SPC, Labelling or PL due to 
new quality, preclinical, clinical or pharmacovigilance 
data 
C.I.4 - Change(s) in the SPC, Labelling or PL due to 
new quality, preclinical, clinical or pharmacovigilance 
data 
II/0011 
To update sections 4.2 and 5.1 of the SmPC in order 
30/03/2023 
26/04/2023 
SmPC and PL 
For more information, please refer to the Summary of 
Product Characteristics. 
to update the information for immune response after 
subcutaneous administration based on final results 
from study V114-P033 (EudraCT: 2019-003644-68), 
in accordance with Article 46 of the paediatric 
regulation. V114-P033 is a phase 3 Active-
Comparator controlled study to evaluate the Safety, 
Tolerability, and Immunogenicity of V114 in Healthy 
Japanese Infants. 
The Package Leaflet is updated accordingly. 
C.I.4 - Change(s) in the SPC, Labelling or PL due to 
new quality, preclinical, clinical or pharmacovigilance 
data 
PSUSA/10975
Periodic Safety Update EU Single assessment - 
09/02/2023 
n/a 
PRAC Recommendation - maintenance 
/202207 
pneumococcal polysaccharide conjugate vaccine (15 
valent, adsorbed) 
IB/0012 
B.I.d.1.a.4 - Stability of AS - Change in the re-test 
29/11/2022 
n/a 
period/storage period - Extension or introduction of a 
Page 3/6 
 
 
 
 
 
 
 
 
 
 
 
 
 
re-test period/storage period supported by real time 
data 
IA/0010 
B.II.e.7.b - Change in supplier of packaging 
03/11/2022 
n/a 
components or devices (when mentioned in the 
dossier) - Replacement or addition of a supplier 
II/0001 
Extension of indication to include treatment of 
15/09/2022 
21/10/2022 
SmPC, Annex 
Please refer to Scientific Discussion Vaxneuvance-H-C-
infants, children and adolescents from 6 weeks to 
II, Labelling 
5477-II-0001. 
less than 18 years of age for active immunisation for 
and PL 
the prevention of invasive disease, pneumonia and 
acute otitis media for Vaxneuvance.  As a 
consequence, sections 4.1, 4.2, 4.4, 4.5, 4.8 and 5.1 
of the SmPC are updated. The Package Leaflet is 
updated in accordance.  
Version 2.0 of the RMP has also been submitted.   
In addition, the MAH took the opportunity to update 
the list of local representatives in the Package Leaflet 
and to include editorial changes in the product 
information. 
C.I.6.a - Change(s) to therapeutic indication(s) - 
Addition of a new therapeutic indication or 
modification of an approved one 
IB/0008 
B.II.f.1.b.5 - Stability of FP - Extension of the shelf 
16/09/2022 
26/04/2023 
SmPC 
Product information was updated to reflect the extension of 
life of the finished product - Biological/immunological 
medicinal product in accordance with an approved 
stability protocol 
shelf-life for Vaxneuvance suspension for injection in pre-
filled syringe from 24 months to 30 months. 
II/0007/G 
This was an application for a group of variations. 
01/09/2022 
n/a 
Page 4/6 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
B.II.b.2.a - Change to importer, batch release 
arrangements and quality control testing of the FP - 
Replacement/addition of a site where batch 
control/testing takes place 
B.II.b.1.c - Replacement or addition of a 
manufacturing site for the FP - Site where any 
manufacturing operation(s) take place, except batch 
release/control, and secondary packaging, for 
biol/immunol medicinal products or pharmaceutical 
forms manufactured by complex manufacturing 
processes 
PSUSA/10975
Periodic Safety Update EU Single assessment - 
01/09/2022 
n/a 
PRAC Recommendation - maintenance 
/202201 
pneumococcal polysaccharide conjugate vaccine (15 
valent, adsorbed) 
IB/0005 
B.I.b.2.a - Change in test procedure for AS or 
19/07/2022 
n/a 
starting material/reagent/intermediate - Minor 
changes to an approved test procedure 
IA/0006 
A.4 - Administrative change - Change in the name 
01/07/2022 
n/a 
and/or address of a manufacturer or an ASMF holder 
or supplier of the AS, starting material, reagent or 
intermediate used in the manufacture of the AS or 
manufacturer of a novel excipient 
IG/1515 
A.4 - Administrative change - Change in the name 
14/06/2022 
n/a 
and/or address of a manufacturer or an ASMF holder 
or supplier of the AS, starting material, reagent or 
intermediate used in the manufacture of the AS or 
Page 5/6 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
manufacturer of a novel excipient 
IB/0003 
B.II.e.5.a.2 - Change in pack size of the finished 
22/04/2022 
21/10/2022 
SmPC, 
product - Change in the number of units (e.g. 
tablets, ampoules, etc.) in a pack - Change outside 
the range of the currently approved pack sizes 
Labelling and 
PL 
Page 6/6 
 
 
 
 
 
 
 
 
 
